Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.

Studied

Whether testosterone changes tracked breast enlargement during intermittent enzalutamide treatment for recurrent prostate cancer.

Who / model

38 patients with recurrent prostate cancer received intermittent 3-month enzalutamide courses without androgen-deprivation treatment. Testosterone and adverse events were monitored prospectively.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Median peak testosterone was 832.5 ng/dL. Breast-enlargement symptoms occurred in 42% of patients. Neither peak testosterone nor time with elevated testosterone correlated with these symptoms, and symptoms during one course did not reliably predict the next.

Limits

This small prostate-cancer cohort does not establish what causes breast symptoms in other settings, such as testosterone therapy.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary